The prediction model of this study examined several additional biomarkers: CD62L, CD62E, CD62P and VCAM-1, and found that CD62L and VCAM-1 demonstrated a high value for predicting a renal recovery in patients with S-AKI. The gene discussed is SELL; the disease is acute kidney injury.